Chronic Hepatitis B Virus Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Chronic Hepatitis B Virus Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Chronic Hepatitis B Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• Over 50+ Chronic Hepatitis B Virus companies are evaluating 55+ Chronic Hepatitis B Virus pipeline therapies in various stages of development, and their anticipated acceptance in the Chronic Hepatitis B Virus market would significantly increase market revenue.
• The leading Chronic Hepatitis B Virus Companies working in the market include Vedanta Biosciences, Gilead Sciences, Dong-ASTCo, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, and others.
• Promising Chronic Hepatitis B Virus Pipeline Therapies in the various stages of development include BRII-835, Entecavir, EYP001a, Entecavir, RBD1016, ABI-H3733, LW231 tablets, and others.
• April 2024: Gilead Sciences announced a study of Phase 2 clinical trials for TAF. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
• April 2024: Ascletis Pharmaceuticals Co., Ltd. announced a study of Phase 2 clinical trials for ASC42 10mg and Entecavir. This is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic hepatitis B virus.

Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis B Virus Pipeline landscape @ Chronic Hepatitis B Virus Pipeline Outlook Report- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Chronic Hepatitis B Virus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chronic Hepatitis B Virus NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Hepatitis B Virus Overview
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously.

Find out more about Chronic Hepatitis B Virus Therapeutics Assessment @ Chronic Hepatitis B Virus Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hepatitis B Virus Emerging Therapies Profile

• Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand's HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.

• RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.

Chronic Hepatitis B Virus Therapeutics Assessment
There are approx. 50+ key Chronic Hepatitis B Virus companies which are developing the Chronic Hepatitis B Virus therapies. The Chronic Hepatitis B Virus companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.

DelveInsight's Chronic Hepatitis B Virus pipeline report covers around 55+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Chronic Hepatitis B Virus Pipeline Therapies @ Chronic Hepatitis B Virus Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage- Global
• Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-ASTCo, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, and others.
• Chronic Hepatitis B Virus Pipeline Therapies- BRII-835, Entecavir, EYP001a, Entecavir, RBD1016, ABI-H3733, LW231 tablets, and others.
• Chronic Hepatitis B Virus Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Chronic Hepatitis B Virus Pipeline Companies and Therapies, click here @ Chronic Hepatitis B Virus Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Hepatitis B Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pradefovir: Ligand Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RG6346: Dicerna Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. VIR-3434: Vir Biotechnology
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. SBT8230: Silverback Therapeutics
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Chronic Hepatitis B Virus Infection Key Companies
24. Chronic Hepatitis B Virus Infection Key Products
25. Chronic Hepatitis B Virus Infection - Unmet Needs
26. Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
27. Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
28. Chronic Hepatitis B Virus Infection Analyst Views
29. Chronic Hepatitis B Virus Infection Key Companies
30. Appendix

Got Queries? Find out the related information on Chronic Hepatitis B Virus Mergers and acquisitions and chronic Hepatitis B Virus Licensing Activities @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.